Corcept Sees Cushing's Business At $3 Billion To $5 Billion In 2030 With Relacorilant
The new endocrinology president put a number on the drug's potential as an FDA decision looms on December 17.
Corcept Therapeutics, a drug company that treats disorders by modulating the hormone cortisol, expects its Cushing syndrome sales to reach between $3 billion and $5 billion in 2030 if relacorilant is available, endocrinology division president Justin Gunn said on the company's third-quarter earnings call on Tuesday. The FDA is due to decide on the drug by December 17.
A $2 billion floor, a faster path
Gunn, who took the role at the beginning of October after running sales for the oncology division, said the current Cushing syndrome business should produce at least $2 billion in annual revenue by the end of this decade. Relacorilant's availability would speed that growth to the $3 billion to $5 billion range in 2030, he said.
He tied the outlook to an October consensus report from the American Diabetes Association, which cites the company's CATALYST study and recommends screening for hypercortisolism in patients whose blood sugar stays high despite multiple glucose-lowering drugs. CEO Joseph Belanoff said the study found 24% of patients with difficult-to-control diabetes had hypercortisolism.
Asked by an analyst at H.C. Wainwright about switching patients, Gunn said the focus for relacorilant will be treatment-naive patients, not those already on Korlym or its authorized generic. He called the opportunity "much larger than the current base" of those products.
The FDA question management would not answer
An analyst at Truist asked whether the company had discussed labeling or liver injury signals with the FDA. Charlie Robb, the chief business officer, who Belanoff said runs regulatory activities, said he could not comment beyond the December 17 date.
Robb said the FDA issued a complete response letter at the end of last year and then asked for no new data, but for a global statistical test across glucose, weight and hypertension endpoints. The company resubmitted its application in June, and the FDA accepted it for review.
Quarter: revenue up 64%
Chief Financial Officer Atabak Mokari said third-quarter revenue was $340.5 million, up 33% from the second quarter and 64% from a year earlier. Korlym and the authorized generic brought in $249.1 million, and the ovarian cancer drug Lifyorli, which the transcript renders as Lifioly, brought in $91.4 million.
Net income was $126.8 million, against $43 million in the second quarter and $19.7 million a year earlier. Cash and investments reached $662 million at September 30, up $118 million in the quarter. The company reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion; Mokari said the range has been raised a few times this year already.
Corcept's market value was about $8.7 billion.
The FDA's decision on relacorilant in Cushing syndrome is due December 17.